"THE WAY FORWARD FOR HTA COOPERATION – THE VIEWS OF STAKEHOLDERS"

09 JULY 2018

Location :
Room Alcide de Gasperi, Charlemagne building, Rue de la Loi 170, 1049 Brussels, Belgium

Agenda

9:00 -10:00 Registration and welcome coffee

10:00-11:00 Opening session

- Welcome and opening
  - Vytenis Andriukaitis, *European Commissioner for Health and food safety*
  - Soledad Cabezón Ruiz, *Member of European Parliament (Rapporteur, ENVI Committee)*
  - Clemens Auer, *Director General, Ministry of Health, Austria (EU presidency)*
  - Dimitris Dimitriadis, *Member of European Economic and Social Committee (Rapporteur HTA)*

COFFEE BREAK

11:15- 12:30 Session 1 – Engaging with patients and clinicians on HTA: Current status and future direction

The session will begin with a scene-setting presentation by a representative of the patient community, followed by a multi-stakeholder panel discussion.

- The session will discuss the involvement of the patients and health care providers in the joint work, in particular in the joint clinical assessments, the joint scientific consultation as well the broader strategic work, such as developing the work programmes of the Coordination Group, identifying emerging technologies, and ensuring that the outcomes and factors relevant to patients are considered.

- **Presenter**
  - Eric Low, *Patient representative, Amyloidosis Research Consortium, UK*

- **Panellists**
  - Martin Danner, *Representative of patient organisations, Federal Joint Committee (G-BA), Germany*
  - Alma Hanevy, *Stakeholder engagement lead, National Centre for Pharmacoeconomics (NCPE), Ireland*
  - Mirjana Huic, *Assistant Director, Agency for Quality and Accreditation in Health Care and Social Welfare, Croatia*
  - Jacques de Haller, *President, Standing Committee of European Doctors (CPME)*

Chaired by Nicola Bedlington*, Secretary General, European Patients' Forum (EPF)*

LUNCH

14:00-15:15 Session 2 - Generating evidence that meets the needs of patients and health system decision makers

The session will start with a scene-setting presentation by a representative from an HTA body, followed by a multi-stakeholder panel discussion.

- The discussion on the pre-market phase will have a specific focus on the joint scientific consultation and how it can support the generation of evidence that meets the needs of HTA bodies. The discussion will feature expert views from the three key parties – HTA bodies, industry and the European Medicines Agency-, as well as enable patients and payers to provide their views and recommendations.

- **Presenter**
  - François Meyer, *Advisor to the President, French National Authority for Health (HAS), France*
- **Panellists**
  - Adam Parnaby, *Director, Market Access Policy, Celgene*
  - Jane Moseley, *Senior Scientific Officer, European Medicines Agency*
  - Francesca Cattarin, *Health Policy Officer, European Consumer organisation (BEUC)*
  - Menno Aarnout*, Executive director, International Association of Mutual Benefit Societies (AIM)*

Chaired by François Houyez, *Treatment Information and Access Director, EURORDIS-Rare Diseases Europe*

COFFEE BREAK

15:45-17:00 Session 3 - Managing uncertainty in the post-launch phase

The session will start with a scene-setting presentation by the health care provider representative, followed by a multi-stakeholder panel discussion.

- The discussion will focus on opportunities in the post-launch evidence generation space and the potential for updates of possible future joint clinical assessments using newly

generated evidence. The session will also explore how the post-launch evidence generation can benefit from the opportunities in the Digital Single Market.

- **Presenter**
  - Piotr Szymanski, *Associate Professor of Cardiology, European Society for Cardiology*
- **Panellists**
  - Jo De Cock, *General Manager, National Institute of Health and Disability Insurance (RIZIV/INAMI), Belgium*
  - Agnese Cangini *Health Economist, Italian Medicines Agency (AIFA), Italy*
  - Pascale Brasseur, *Global Reimbursement Director, Spine & Biologics, Medtronic*
  - Ansgar Hebborn, *Head of Global Market Access Policy, Roche Pharmaceuticals*

Chaired by Rosanna Tarricone, *Associate Dean, Bocconi University School of Management, Italy*

17:00-17:30 Closing remarks

- Marcus Guardian, Chief Operating Officer, EUnetHTA Joint Action
- Xavier Prats Monné, European Commission, Director General for Health and Food Safety

17.30 -18.30 Closing reception